-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPS-2071 in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPS-2071 in Irritable Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPS-2071 in Irritable Bowel Syndrome Drug Details: OPS-2071 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OP-101 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OP-101 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KGYY-15 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KGYY-15 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KGYY-15 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Livmoniplimab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Livmoniplimab in Non-Small Cell Lung Cancer Drug Details: Livmoniplimab (ABBV-151)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Palazestrant in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palazestrant in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palazestrant in Metastatic Breast Cancer Drug Details: Palazestrant (OP-1250) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palazestrant in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palazestrant in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palazestrant in...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Esophageal Cancer Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is a...
-
Sector Analysis
NewUnited Kingdom (UK) Mother’s Day Market Analysis, Trends, Consumer Attitudes and Buying Dynamics, 2024 Update
The UK Mother's Day 2024 report forms part of GlobalData's Retail Occasions series, and offers a comprehensive insight into the consumer dynamics and spending habits of UK consumers for Mother's Day. The report analyses the major players, the main trends, and consumer attitudes. The proportion of UK consumers that participated in Mother’s Day has increased this year, but those spending on the event fell. This has largely been driven by consumers choosing to spend time with their families rather than...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Diffuse Large B-Cell Lymphoma Drug Details: NKTR-255 is under development for the treatment...
-
Product Insights
Mycobacterium avium Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycobacterium avium Infections - Drugs In Development, 2023’, provides an overview of the Mycobacterium avium Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycobacterium avium Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...